Biological treatment of rheumatic diseases

Česká verzia

Authors: L. Procházková; J. Böhmová; M. Souček
Authors place of work: II. interní klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2006; 52(6): 632-639
Category: Review

Summary

During recent two decades the progress in the understanding of the pathogenesis of the autoimmune diseases have led to new treatment targets, whose achievement claims new therapeutic advancings. Biological drugs complete or replace conventional immunosuppressive therapies in the treatment of autoimmune diseases. In the treatment of rheumatic diseases are currently used TNF α inhibitors and blockade of the IL-1, in phase of clinical trials or actual registration are agents blocking IL-6, the antibodies against B cell and inhibition of activation of T-cells by costimulating blockade with CTLA4Ig. In the Czech Republic are for treating of rheumatic diseases approved TNF blocking drugs. Treatment with this drugs is centred in biological therapy centres and patients are enroled into Registry of patients treated with anti TNF α drugs (ATTRA), which enable long-term observation of efficacy and toxicity.

Key Words:
rheumatic diseases - TNF α - TNF blocking agents - biological treatment

Zdroje

1. Maini RN, Bredweld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563.

2. Pavelka K et al. Farmakoterapie revmatických onemocnění.Praha: Grada Publishing 2005: 147-163.

3. Maini R, St.Clair EW, Breedweld F et al. Infliximab versus placebo in rheumatoid arthritis patiens receiving concomitant methotrexate: a randomised phase III.trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.

4. HumiraTM Package Insert

5. ENBREL® Package Insert

6. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement of biological agents, specifically tumour necrosis factor α (TNF α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64: iv2-iv14.

7. Pavelka K. Biologická léčba revmatoidní artritidy a dalších revmatických onemocnění. Remedia 2005; 1: 53-66.

8. Klareskog L, van Der Heide D, Jager JP et al. Therapeutic effect of combination of etanercept and MTX compared with each treatment alone in patients with rheumatoid arthritis: double blind randomised trial. Lancet 2004; 363: 675-85.

9. Lipsky PE, van der Heijde DM, St Clain EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.

10. St Clair EW, van der Heijde DM, Smolen JS et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-3443.

11.Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patiens taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003; 48: 35-45

12. Burmestr GR, van der Gutte LBA et al. Sustained efficacy of adalimumab monotherapy for more than four years in DMARD-refractory RA. EULAR 2003; Lisabon, Abstract.

13. Breedveld FC, Kavanaugh AF et al. Early treatment of RA with adalimumab (Humira) plus MTX vs adalimumab alone or MTX alone: The Premier study Arthritis Rheum 2004; ACR, Abstract.

14. Weinblatt ME, Kremer, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.

15. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-1593.

16. Klareskog L, van der Heijde D, de Jager JP et al. TEMPO study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-681.

17. Perez J, Kupper H, Spencer-Green G. Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe. In: Program and abstrakt of the European League Against Rheumatism 2005 Annual Scientific Meeting; June 8-11, 2005; Vienna, Austria. Abstrakt OP0093.

18. Vencovský J, Tezová D, Krofta K et al. Doporučení České revmatologické společnosti k biologické léčbě blokádou TNF - doplněk standardních léčebných postupů u revmatoidní artritidy. Čes Revmatol 2004; 12: 20-29.

19. Prevo ML, van´t Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Artritis Rheum 1995; 38: 440-448.

20. Gladman D. In: Wright V, Helliwell PS (eds). Psoriatic Arthritis in Balliereś Clinical Rheumatology. London: Balliere Tindall 1994; 379.

21. Gladman DD, Hing EN, Schentag CT et al. Remission in psoriatic arthritis. J Rheumatol 2001; 28: 1045-1048.

22. Fraser A, Fearon U, Billinghurst RC et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003; 48: 3085-3095.

23. Ritchlin C, Haas-Smith SA, Hicks D et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544 -1552.

24. Štolfa J, Pavelka K, Vencovský J. Standartní postupy v léčbě psoritické artritidy. Čes Revmatol 2005; 13: 97-105.

25. Ferraz MB, Tugwell B, Goldsmith CH et al. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990; 70:1482.

26. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-1352.

27. Gratacos J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927-931.

28. McGonagle D, Khan, Marzo-Ortega H et al. Enthesitis in spondylarthropathy. Curr Opin Rheumatol 1999; 11: 244-250.

29. Grom AA, Murray KJ, Luyrink L et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703-1710.

30. Pavelka K, Štolfa J, Vencovský J. Doporučení České revmatologické společnosti k biologické léčbě blokádou TNF - Doplněk standardních léčebných postupů u ankylozující spondylitidy. Čes Revmatol 2004; 12: 30-39.